We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our
Privacy Policy
At Profacgen, our Novel E3 Ligase Discovery Service identifies and characterizes previously unexplored E3 ubiquitin ligases to expand the targeted protein degradation toolbox, enabling tissue-specific degraders and novel therapeutic strategies beyond established VHL, CRBN, MDM2, and cIAP platforms.
Ubiquitination is a highly specific regulatory mechanism governing diverse cellular processes—including protein internalization, lysosomal targeting, interaction modulation, subcellular distribution, transcription, DNA repair, and signal transduction. E3 ligases are involved in numerous diseases and represent promising therapeutic targets. Despite over 600 known E3 ligases, only a few have been utilized in degrader development. Profacgen employs phage display and small-molecule libraries to discover novel E3 ligases and assess their degrader potential.
Overview
Expanding the E3 ligase repertoire is critical for advancing targeted protein degradation. Novel E3 ligases offer distinct advantages that address limitations of current platforms:
Tissue specificity: E3 ligases with restricted expression profiles enable degradation in specific tissues or cell types, reducing systemic toxicity and improving therapeutic windows for indications requiring localized protein elimination
Disease relevance: Disease-specific E3 ligase upregulation or hijacking can be exploited to achieve selective degradation in pathological contexts while sparing healthy tissues
Resistance mechanisms: Access to alternative E3 ligases circumvents resistance arising from mutations or downregulation of commonly used recruiters such as VHL or CRBN
Expanded target scope: Novel E3 ligases may recognize distinct substrate motifs or operate in unique cellular compartments, enabling degradation of targets refractory to established ligase platforms
Our Discovery Workflow
Profacgen employs a systematic, multi-stage workflow to identify and prioritize novel E3 ligases with degrader utility:
Candidate Identification
Comprehensive mining of the E3 ligase landscape to identify unexplored candidates.
Database mining: Systematic analysis of genomic, proteomic, and ubiquitinome databases to catalog understudied E3 ligases
Literature curation: Integration of emerging research on E3 ligase biology, disease associations, and substrate specificities
Phylogenetic analysis: Identification of E3 ligase family members with divergent substrate recognition properties
Bioinformatics Analysis
Computational evaluation of E3 ligase properties relevant to degrader design.
Domain architecture: Analysis of substrate recognition domains, catalytic cores, and autoinhibitory elements
Druggability assessment: In silico prediction of ligandable surfaces and protein-protein interaction interfaces
Expression mapping: Tissue-specific and disease-associated expression pattern analysis
Expression Profiling
Experimental validation of candidate E3 ligase expression and activity.
Transcriptomic analysis: Quantitative expression profiling across normal and disease tissues by RNA-seq and qPCR
Proteomic detection: Mass spectrometry-based protein quantification and post-translational modification mapping
Subcellular localization: Immunofluorescence and fractionation studies to determine compartment-specific activity
Functional Prioritization
Ranking of candidates based on degrader-relevant functional criteria.
Activity assessment: Autoubiquitination assays and E2 conjugating enzyme profiling to confirm catalytic competence
Substrate repertoire: Proteome-wide ubiquitination profiling to map endogenous substrate specificities
Profacgen provides comprehensive characterization of novel E3 ligases to enable rational degrader design:
Sequence analysis: Full-length cDNA cloning, isoform identification, and mutational mapping to define functional domains and variant effects
Structural analysis: Homology modeling, cryo-EM, and X-ray crystallography to elucidate substrate recognition mechanisms and identify ligandable surfaces
Ligase activity evaluation: In vitro ubiquitination assays with model substrates, E2 profiling, and kinetic parameter determination to quantify catalytic efficiency
Target compatibility assessment: Evaluation of candidate E3 ligases for compatibility with diverse target classes, linker chemistries, and cellular degradation contexts
Validation Strategies
Rigorous cellular and biochemical validation confirms novel E3 ligase utility in degrader applications:
Cell-based validation: Overexpression and knockdown studies in relevant cell lines to assess E3 ligase activity, substrate turnover, and engagement with heterobifunctional degraders
Ubiquitination studies: Quantitative detection of target ubiquitination by immunoprecipitation-mass spectrometry, TUBE-based enrichment, and ubiquitin chain topology analysis
Degradation studies: Time-course and dose-response evaluation of target protein levels following degrader treatment, with confirmation of proteasome dependence and ternary complex requirement
PROTAC development: Design of heterobifunctional degraders recruiting novel E3 ligases to achieve tissue-specific or disease-selective target elimination
Molecular glue discovery: Identification of E3 ligases amenable to substrate reprogramming, enabling glue-like mechanisms for targets lacking druggable pockets
Tissue-specific degraders: Exploitation of E3 ligases with restricted expression profiles to limit degradation to target tissues and minimize systemic exposure
Novel TPD platforms: Establishment of entirely new degradation modalities including lysosomal-targeting chimeras, autophagy-targeting chimeras, and antibody-based degraders leveraging alternative E3 ligases
Deliverables
Profacgen provides structured documentation to advance novel E3 ligases from discovery to degrader development:
Parameter
Description
Candidate Lists
Prioritized E3 ligase candidates with expression data, druggability scores, functional annotations, and rationale for selection
Phage Display Expertise: Proprietary phage screening platform enables rapid selection of high-affinity E3 ligase variants and substrate recognition modules.
Comprehensive E3 Landscape Coverage: Systematic mining of the >600-member E3 ligase superfamily to identify candidates beyond the limited established toolkit.
Integrated Discovery-to-Degrader Pipeline: Seamless progression from candidate identification through characterization, validation, and degrader design within a single platform.
Disease-Centric Prioritization: Expression and functional profiling aligned to therapeutic indications ensures selection of clinically relevant E3 ligases.
Representative Program Scenarios
Scenario 1: Phage Display Selection of a Brain-Specific E3 Ligase
Program Context:
A neurodegeneration program required targeted protein degradation restricted to the central nervous system to avoid systemic toxicity. Established E3 ligases such as VHL and CRBN are ubiquitously expressed, precluding tissue-specific applications.
Objective:
To identify and validate a brain-enriched E3 ligase suitable for CNS-restricted PROTAC development, with confirmed catalytic activity and degrader compatibility.
Approach:
Profacgen performed transcriptomic profiling across 50 human tissues to identify E3 ligases with >10-fold brain enrichment. Top candidates were validated by qPCR and immunohistochemistry in human brain sections. A lead candidate was subjected to phage display selection using immobilized substrate peptides to identify high-affinity recognition motifs. Catalytic activity was confirmed by in vitro ubiquitination assays, and degrader compatibility was tested by fusing a known target warhead to a candidate-derived recruiting peptide.
Outcome:
The identified E3 ligase demonstrated selective expression in neurons and astrocytes with negligible peripheral tissue presence. Phage display yielded a recruiting peptide with nanomolar affinity. The resulting brain-specific PROTAC induced potent target degradation in primary neuronal cultures with no activity in hepatocytes, validating tissue-restricted degradation and supporting CNS therapeutic development.
Scenario 2: Novel E3 Ligase for Resistant Oncology Targets
Program Context:
An oncology degrader program encountered resistance due to CRBN downregulation in tumor cells following chronic treatment. The team required an alternative E3 ligase with similar degradation efficiency but distinct resistance profile.
Objective:
To discover a novel E3 ligase with comparable substrate scope to CRBN but differential regulation, enabling degrader efficacy in resistant settings.
Approach:
Profacgen analyzed CRBN-dependent and CRBN-independent ubiquitinome datasets to identify E3 ligases with overlapping substrate preferences. Candidates were ranked by expression in CRBN-low tumor cell lines and validated by shRNA-mediated knockdown studies. A top candidate was characterized by structural modeling, E2 profiling, and substrate repertoire mapping. A panel of PROTACs recruiting the novel E3 ligase was synthesized and tested in CRBN-proficient and CRBN-deficient models.
Outcome:
The novel E3 ligase maintained robust expression in CRBN-resistant cells and supported efficient target degradation with comparable potency to CRBN-based degraders. Cross-resistance profiling confirmed orthogonal resistance mechanisms, supporting the candidate as a viable alternative for combination or sequential degrader therapy.
Q: How many E3 ligases are potentially exploitable for degrader design?
A: Over 600 E3 ligases have been identified in the human genome, yet fewer than 10 are routinely used in degrader design. The vast majority remain unexplored. Our platform systematically evaluates this untapped reservoir to identify candidates with favorable expression, activity, and druggability profiles.
Q: What is phage display and how does it apply to E3 ligase discovery?
A: Phage display is a selection technique that presents peptide or protein libraries on bacteriophage surfaces. We immobilize E3 ligands or substrate peptides and screen for high-affinity binding variants. This enables rapid identification of optimal recognition motifs and E3 ligase variants with desired binding properties.
Q: Can novel E3 ligases address resistance to existing degraders?
A: Yes. Resistance to VHL- or CRBN-based degraders often arises from ligase downregulation, mutation, or altered expression. Alternative E3 ligases with orthogonal regulation provide escape routes from resistance. Our discovery platform prioritizes candidates with distinct expression patterns and regulatory mechanisms.
Q: How do you validate that a novel E3 ligase supports target degradation?
A: We validate through a tiered approach: in vitro ubiquitination assays confirm catalytic activity; cellular overexpression and knockdown studies assess target turnover; and heterobifunctional degrader prototypes demonstrate proteasome-dependent degradation with ternary complex formation.
Q: What is the typical timeline for novel E3 ligase discovery?
A: Candidate identification and bioinformatics analysis require 4–6 weeks. Expression profiling and functional prioritization add 6–8 weeks. Full characterization and validation typically span 3–4 months. Degrader prototype testing extends the timeline by an additional 2–3 months depending on complexity.
Q: Can you discover E3 ligases for specific tissues or diseases?
A: Yes. Our discovery workflow incorporates tissue-specific expression profiling and disease-associated functional analysis from the outset. We prioritize candidates with restricted expression in target tissues or altered activity in disease states, enabling tailored degrader strategies.
Online Inquiry
Fill out this form and one of our experts will respond to you within one business day.
